mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for LYN
Gene summary
Basic gene Info.Gene symbolLYN
Gene nameLYN proto-oncogene, Src family tyrosine kinase
CytomapUCSC genome browser: 8q13
Type of geneprotein-coding
Descriptionlck/Yes-related novel protein tyrosine kinasetyrosine-protein kinase Lynv-yes-1 Yamaguchi sarcoma viral related oncogene homolog
Modification date20141207
dbXrefs MIM : 165120
Ensembl : ENSG00000254087
HPRD : 01301
Vega : OTTHUMG00000044345
ProteinUniProt: P07948
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_LYN
BioGPS: 4067
PathwayNCI Pathway Interaction Database: LYN
Pathway Commons: LYN
ContextiHOP: LYN
ligand binding site mutation search in PubMed: LYN
UCL Cancer Institute: LYN
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0006468protein phosphorylation11517336
GO:0006974cellular response to DNA damage stimulus10891478
GO:0018108peptidyl-tyrosine phosphorylation7682714
GO:0046777protein autophosphorylation7682714
GO:0051272positive regulation of cellular component movement16467205
GO:0070304positive regulation of stress-activated protein kinase signaling cascade10891478

Ligand binding site mutations for LYN
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for LYN
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for LYN from PDB

Differential gene expression and gene-gene network for LYN
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of LYN and the right PPI network was created from samples without mutations in the LBS of LYN. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for LYN
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0019693HIV Infections2Biomarker, GeneticVariation

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for LYN
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB030231-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-YlamineSmall molecule
ApprovedDB06616BosutinibSmall molecule
ApprovedDB08901PonatinibSmall molecule
ApprovedDB09079NintedanibSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of LYN go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of LYN
Multiple alignments for P07948 in multiple species
LBSAA sequence# speciesSpecies
A273NSTKVAVKTLK3Homo sapiens, Mus musculus, Rattus norvegicus
A371RDLRAANVLVS3Homo sapiens, Mus musculus, Rattus norvegicus
D75ALYPYDGIHPD3Homo sapiens, Mus musculus, Rattus norvegicus
D80DGIHPDDLSFK3Homo sapiens, Mus musculus, Rattus norvegicus
D81GIHPDDLSFKK3Homo sapiens, Mus musculus, Rattus norvegicus
E320IYIITEFMAKG2Mus musculus, Rattus norvegicus
E320IYIITEYMAKG1Homo sapiens
E98LEEHGEWWKAK3Homo sapiens, Mus musculus, Rattus norvegicus
F112SKREGFIPSNY2Mus musculus, Rattus norvegicus
F112TKKEGFIPSNY1Homo sapiens
G325EFMAKGSLLDF2Mus musculus, Rattus norvegicus
G325EYMAKGSLLDF1Homo sapiens
G97VLEEHGEWWKA3Homo sapiens, Mus musculus, Rattus norvegicus
H78PYDGIHPDDLS3Homo sapiens, Mus musculus, Rattus norvegicus
H96KVLEEHGEWWK3Homo sapiens, Mus musculus, Rattus norvegicus
I77YPYDGIHPDDL3Homo sapiens, Mus musculus, Rattus norvegicus
K275TKVAVKTLKPG3Homo sapiens, Mus musculus, Rattus norvegicus
L253KLVKKLGAGQF2Mus musculus, Rattus norvegicus
L253KLVKRLGAGQF1Homo sapiens
L374RAANVLVSESL3Homo sapiens, Mus musculus, Rattus norvegicus
M322IITEFMAKGSL2Mus musculus, Rattus norvegicus
M322IITEYMAKGSL1Homo sapiens
N116GFIPSNYVAKV2Mus musculus, Rattus norvegicus
N116GFIPSNYVAKL1Homo sapiens
P114REGFIPSNYVA2Mus musculus, Rattus norvegicus
P114KEGFIPSNYVA1Homo sapiens
P73VVALYPYDGIH3Homo sapiens, Mus musculus, Rattus norvegicus
S115EGFIPSNYVAK3Homo sapiens, Mus musculus, Rattus norvegicus
S326FMAKGSLLDFL2Mus musculus, Rattus norvegicus
S326YMAKGSLLDFL1Homo sapiens
T319PIYIITEFMAK2Mus musculus, Rattus norvegicus
T319PIYIITEYMAK1Homo sapiens
V261GQFGEVWMGYY3Homo sapiens, Mus musculus, Rattus norvegicus
W100EHGEWWKAKSL3Homo sapiens, Mus musculus, Rattus norvegicus
W99EEHGEWWKAKS3Homo sapiens, Mus musculus, Rattus norvegicus
Y117FIPSNYVAKVN2Mus musculus, Rattus norvegicus
Y117FIPSNYVAKLN1Homo sapiens
Y321YIITEFMAKGS2Mus musculus, Rattus norvegicus
Y321YIITEYMAKGS1Homo sapiens
Y72IVVALYPYDGI3Homo sapiens, Mus musculus, Rattus norvegicus
Y74VALYPYDGIHP3Homo sapiens, Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas